Dr. Johnson on Datopotamab Deruxtecan in NSCLC With Actionable Genomic Alterations
Do not invent PMIDs, DOIs, NCT ids, genes, or drugs.
During the 2021 ESMO Congress, preliminary findings from the phase 1 TROPION‑PanTumor01 trial (NCT03401385) were presented. The results demonstrated a 35% overall response rate and a median duration of response of 9.5 months with the antibody‑drug conjugate (ADC) datopotamab deruxtecan in patients with heavily pretreated advanced NSCLC and actionable genomic alterations.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT